Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series-Reference-Cited by-同舟云学术

Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series

Published:2021 Issue:5 Volume:68 Page:613-620
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Ishi Azusa¹,Tanaka Ichidai¹,Iwama Shintaro²,Sakakibara Toshihiro¹,Mastui Toshinori¹,Kobayashi Tomoko²,Hase Tetsunari¹,Morise Masahiro¹,Sato Mitsuo³,Arima Hiroshi²,Hashimoto Naozumi¹

Affiliation:

1. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

2. Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan

3. Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/68/5/68_EJ20-0769/_pdf

Reference27 articles.

1. 1 Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365–1369.

2. 2 Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027–1034.

3. 3 Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261–268.

4. 4 Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, et al. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255–265.

5. 5 Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, et al. (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124: 271–277.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis;European Journal of Endocrinology;2024-06-25

2. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter study;2024-02-15

3. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria;Diseases;2024-02-14

4. Fulminant type 1 diabetes: Focusing on triggering factors;Diabetes/Metabolism Research and Reviews;2023-10-10

5. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer;2023-09-15